(HealthDay News) – Patients with advanced solid tumors receiving cisplatin-based chemotherapy regimens have a significantly higher risk of having a venous thromboembolic event (VTE) compared with those who do not receive a cisplatin-based regimen, according to research published online Nov. 13 in the Journal of Clinical Oncology.

To evaluate the incidence and risk of VTEs associated with cisplatin-based chemotherapy, Sonia Seng, MD, of the Southcoast Centers for Cancer Care in Fairhaven, MA, and colleagues conducted a systematic review and meta-analysis of 38 randomized controlled trials from 1990–2010 involving 8,216 patients with various advanced solid tumors.

The researchers found that the incidence of VTEs in patients treated with cisplatin-based chemotherapy was 1.92%, compared with 0.79% in patients who did not receive cisplatin-based regimens. Cisplatin-based therapy was associated with significantly increased risk of a VTE (relative risk [RR], 1.67). Patients receiving a weekly equivalent cisplatin dose >30mg/m² had the highest risk (RR, 2.71), and increased risks were also noted for patients in trials during 2001–2010 (RR, 1.72).

“We observed a 1.67-fold increase in the risk of VTEs with cisplatin as compared with non-cisplatin-based chemotherapy,” the authors write. “Given the morbidity and mortality associated with VTEs in patients with cancer, our study adds further support to calls for prospective trials of cisplatin-based chemotherapy administered with prophylactic anticoagulation.”

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)